ALPHA-TOCOPHEROL, BETA-CAROTENE LUNG CANCER PREVENTION STUDY

α-生育酚、β-胡萝卜素预防肺癌研究（ATBC 研究）正在研究每日口服α-生育酚（50 mg）和β-胡萝卜素（20 mg）在一项双盲、随机2x2析因试验中 在50 - 69岁男性中预防肺癌的设计试验 吸烟者。 该项目是基于实验和 流行病学研究表明潜在的预防作用 对于这些代理商。 招募发生在1985年至1988年之间， 平均随访6年以上，将于1993年结束。 邮政 对291，000名男性进行了潜在试验参与者的调查筛选 在芬兰南部，76%的人做出了回应。 我们邀请了吸烟者 参与（43，000）13个研究诊所之一，超过29，000人 随机分配到研究中。 每日一粒胶囊方案的依从性 仍然很高（平均97%），平均辍学率低于 每年超过6%。 降低活性药物中的肺癌发病率 组是主要的研究目标;在其他发生的差异 癌症也将被评估。 为支持《公约》， 试验也已完成，包括可行性研究、验证 研究饮食问卷调查，并评估皮肤变黄， β-胡萝卜素给药后的血清水平。 这项试验是与监督合作进行的。 计划和生物统计学分支的部门的癌症预防和 控制和芬兰国家公共卫生研究所。

The Alpha-Tocopherol, Beta-Carotene Lung Cancer Prevention Study (ATBC Study) is investigating the efficacy of daily oral alpha-tocopherol (50 mg) and beta-carotene (20 mg) in a double-blind, randomized 2x2 factorial design trial aimed at preventing lung cancer among 50-69 year old male cigarette smokers. The project is based on experimental and epidemiological research which demonstrates a potential preventive role for these agents. Recruitment took place between 1985-88, and the trial will end in 1993 after an average followup of over 6 years. A postal survey screening for potential trial participants was sent to 291,000 men in southern Finland, and 76% responded. We invited the smokers willing to participate (43,000) to one of 13 study clinics, and over 29,000 were randomized into the study. Compliance to the one capsule daily regimen has remained very high (97% average), and the dropout rate averages less than 6% per year. Reduction of lung cancer incidence in the active agent groups is the primary study goal; differences in the occurrence of other cancers will also be evaluated. Several pilot studies in support of the trial have also been completed including a feasibility study, validation of study dietary questionnaires, and evaluation of skin yellowing and serum levels following beta-carotene administration. This trial is being conducted collaboratively with the Surveillance Program and the Biometry Branch of the Division of Cancer Prevention and Control and with the National Public Health Institute of Finland.